Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Zhong YuanBennett LevitanHsiaowei DengMichael SzarekRupert M BauersachsScott D BerkowitzLloyd P HaskellElliot S BarnathanMarc P BonacaPublished in: Journal of the American Heart Association (2024)
These analyses show a favorable benefit-risk profile of rivaroxaban therapy in the VOYAGER PAD trial, with findings generally consistent between the unweighted and weighted approaches.
Keyphrases
- end stage renal disease
- venous thromboembolism
- atrial fibrillation
- study protocol
- phase iii
- pulmonary embolism
- clinical trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- magnetic resonance
- prognostic factors
- randomized controlled trial
- high resolution
- magnetic resonance imaging
- stem cells
- coronary artery disease
- patient reported outcomes
- acute coronary syndrome
- mass spectrometry
- open label
- network analysis
- replacement therapy